Literature DB >> 21828252

Bioavailability of the glucuronide and sulfate conjugates of genistein and daidzein in breast cancer resistance protein 1 knockout mice.

Ana I Álvarez1, Fernando Vallejo, Borja Barrera, Gracia Merino, Julio G Prieto, Francisco Tomás-Barberán, Juan C Espín.   

Abstract

The dietary polyphenols genistein and daidzein are potent effectors of biological processes. The plasma profile of both isoflavones is governed by the presence of phase II conjugates, mainly glucuronides and sulfates. Breast cancer resistance protein (ABCG2/BCRP) interacts with genistein and daidzein, which are among the natural substrates of the transporter and competitively inhibit ABCG2-mediated drug efflux. ABCG2/BCRP can also transport glucuronide and sulfate conjugates. In this study, we analyzed the plasma levels of aglycones and derived conjugated metabolites, glucuronides, and sulfates, after intragastric administration of these isoflavones to wild-type and Bcrp1(-/-) knockout mice. The results show that overall plasmatic profile is mainly governed by sulfate and glucuronide derivatives, the concentration of which was significantly increased (7- to 10-fold) in Bcrp1(-/-) mice. The total AUC h nM (0-180 min), as the sum of aglycones, glucuronides, and sulfates, was 901 ± 207 in wild-type mice versus 4988 ± 508 in Bcrp1(-/-) mice after genistein administration (50 mg/kg b.wt.); 584.3 ± 90 in wild-type mice versus 4012 ± 612 in Bcrp1(-/-) after daidzein administration (50 mg/kg); and 926 ± 140 in wild-type mice versus 5174 ± 696 in Bcrp1(-/-) after genistein+daidzein administration (25 + 25 mg/kg). Therefore, our results indicate a direct and conclusive Bcrp1 efflux action on phase II metabolites of these isoflavones in vivo and suggest a possible novel concept for ABCG2/BCRP as part of metabolism-driven efflux transport of these conjugates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828252     DOI: 10.1124/dmd.111.040881

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

Review 1.  Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter.

Authors:  Kristin M Bircsak; Lauren M Aleksunes
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

2.  Reevaluation of the roles of ABCG2 in the disposition of genistein.

Authors:  Ana I Alvarez; Fernando Vallejo; Borja Barrera; Gracia Merino; Julio G Prieto; Francisco Tomás-Barberán; Juan C Espín
Journal:  Drug Metab Dispos       Date:  2012-11       Impact factor: 3.922

3.  Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein.

Authors:  Zhen Yang; Wei Zhu; Song Gao; Taijun Yin; Wen Jiang; Ming Hu
Journal:  Drug Metab Dispos       Date:  2012-06-26       Impact factor: 3.922

4.  Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells.

Authors:  Antonio González-Sarrías; Juan Antonio Giménez-Bastida; María Ángeles Núñez-Sánchez; Mar Larrosa; María Teresa García-Conesa; Francisco A Tomás-Barberán; Juan Carlos Espín
Journal:  Eur J Nutr       Date:  2014-04       Impact factor: 5.614

5.  Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter.

Authors:  Kristin M Bircsak; Vivek Gupta; Poi Yu Sofia Yuen; Ludwik Gorczyca; Barry I Weinberger; Anna M Vetrano; Lauren M Aleksunes
Journal:  J Pharmacol Exp Ther       Date:  2016-02-05       Impact factor: 4.030

6.  Glyceollin transport, metabolism, and effects on p-glycoprotein function in Caco-2 cells.

Authors:  Chukwuemezie Chimezie; Adina C Ewing; Syeda S Quadri; Richard B Cole; Stephen M Boué; Christopher F Omari; Melyssa Bratton; Elena Glotser; Elena Skripnikova; Ian Townley; Robert E Stratford
Journal:  J Med Food       Date:  2014-01-29       Impact factor: 2.786

7.  Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP.

Authors:  Shufan Ge; Taijun Yin; Beibei Xu; Song Gao; Ming Hu
Journal:  Pharm Res       Date:  2015-10-26       Impact factor: 4.200

Review 8.  Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME.

Authors:  Zhen Yang; Kaustubh Kulkarni; Wei Zhu; Ming Hu
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

9.  Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.

Authors:  Christopher Rowbottom; Alicia Pietrasiewicz; Taras Tuczewycz; Richard Grater; Daniel Qiu; Sudarshan Kapadnis; Patrick Trapa
Journal:  Pharmacol Res Perspect       Date:  2021-04

Review 10.  The Vascular Effects of Isolated Isoflavones-A Focus on the Determinants of Blood Pressure Regulation.

Authors:  Henrique Silva
Journal:  Biology (Basel)       Date:  2021-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.